Early Detection of Multiple Cancers - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB510248116

Publication Date:

October 22, 2024

Pages:

132

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Early Detection of Multiple Cancers is a diagnosis and treatment method specifically for early-stage cancer patients, with the purpose of early detection and early treatment, so as to reduce the pain, mental and economic burden of patients. Strive for early recovery of cancer patients through early diagnosis and treatment of cancer.
The global market for Early Detection of Multiple Cancers was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
North American market for Early Detection of Multiple Cancers was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Early Detection of Multiple Cancers was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for Early Detection of Multiple Cancers was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of Early Detection of Multiple Cancers include Grail, Exact Sciences, Foundation Medicine, AnchorDx, Guardant Health, Burning Rock Biotech, GENECAST, Labporatory for Advanced Medicine and Health Group and Singlera Genomics, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Early Detection of Multiple Cancers, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Early Detection of Multiple Cancers by region & country, by Type, and by Application.
The Early Detection of Multiple Cancers market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Early Detection of Multiple Cancers.
Market Segmentation
By Company
Grail
Exact Sciences
Foundation Medicine
AnchorDx
Guardant Health
Burning Rock Biotech
GENECAST
Labporatory for Advanced Medicine and Health Group
Singlera Genomics
Johns Hopkins Medicine
Bioscience
Genetron Holdings
Shenzhen Ruisi
Shanghai Majorbio Bio-Pharm Technology
Shanghai Gurong
Segment by Type:
Liquid Biopsy
Gene Panel
Others
Segment by Application
Hospitals
Diagnostic Laboratories
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Early Detection of Multiple Cancers manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Early Detection of Multiple Cancers in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Early Detection of Multiple Cancers in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Market Overview
1.1 Early Detection of Multiple Cancers Product Introduction
1.2 Global Early Detection of Multiple Cancers Market Size Forecast
1.3 Early Detection of Multiple Cancers Market Trends & Drivers
1.3.1 Early Detection of Multiple Cancers Industry Trends
1.3.2 Early Detection of Multiple Cancers Market Drivers & Opportunity
1.3.3 Early Detection of Multiple Cancers Market Challenges
1.3.4 Early Detection of Multiple Cancers Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Early Detection of Multiple Cancers Players Revenue Ranking (2023)
2.2 Global Early Detection of Multiple Cancers Revenue by Company (2019-2024)
2.3 Key Companies Early Detection of Multiple Cancers Manufacturing Base Distribution and Headquarters
2.4 Key Companies Early Detection of Multiple Cancers Product Offered
2.5 Key Companies Time to Begin Mass Production of Early Detection of Multiple Cancers
2.6 Early Detection of Multiple Cancers Market Competitive Analysis
2.6.1 Early Detection of Multiple Cancers Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Early Detection of Multiple Cancers Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Early Detection of Multiple Cancers as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Liquid Biopsy
3.1.2 Gene Panel
3.1.3 Others
3.2 Global Early Detection of Multiple Cancers Sales Value by Type
3.2.1 Global Early Detection of Multiple Cancers Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Early Detection of Multiple Cancers Sales Value, by Type (2019-2030)
3.2.3 Global Early Detection of Multiple Cancers Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospitals
4.1.2 Diagnostic Laboratories
4.1.3 Others
4.2 Global Early Detection of Multiple Cancers Sales Value by Application
4.2.1 Global Early Detection of Multiple Cancers Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Early Detection of Multiple Cancers Sales Value, by Application (2019-2030)
4.2.3 Global Early Detection of Multiple Cancers Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Early Detection of Multiple Cancers Sales Value by Region
5.1.1 Global Early Detection of Multiple Cancers Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Early Detection of Multiple Cancers Sales Value by Region (2019-2024)
5.1.3 Global Early Detection of Multiple Cancers Sales Value by Region (2025-2030)
5.1.4 Global Early Detection of Multiple Cancers Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Early Detection of Multiple Cancers Sales Value, 2019-2030
5.2.2 North America Early Detection of Multiple Cancers Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Early Detection of Multiple Cancers Sales Value, 2019-2030
5.3.2 Europe Early Detection of Multiple Cancers Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Early Detection of Multiple Cancers Sales Value, 2019-2030
5.4.2 Asia Pacific Early Detection of Multiple Cancers Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Early Detection of Multiple Cancers Sales Value, 2019-2030
5.5.2 South America Early Detection of Multiple Cancers Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Early Detection of Multiple Cancers Sales Value, 2019-2030
5.6.2 Middle East & Africa Early Detection of Multiple Cancers Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Early Detection of Multiple Cancers Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Early Detection of Multiple Cancers Sales Value
6.3 United States
6.3.1 United States Early Detection of Multiple Cancers Sales Value, 2019-2030
6.3.2 United States Early Detection of Multiple Cancers Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Early Detection of Multiple Cancers Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Early Detection of Multiple Cancers Sales Value, 2019-2030
6.4.2 Europe Early Detection of Multiple Cancers Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Early Detection of Multiple Cancers Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Early Detection of Multiple Cancers Sales Value, 2019-2030
6.5.2 China Early Detection of Multiple Cancers Sales Value by Type (%), 2023 VS 2030
6.5.3 China Early Detection of Multiple Cancers Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Early Detection of Multiple Cancers Sales Value, 2019-2030
6.6.2 Japan Early Detection of Multiple Cancers Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Early Detection of Multiple Cancers Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Early Detection of Multiple Cancers Sales Value, 2019-2030
6.7.2 South Korea Early Detection of Multiple Cancers Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Early Detection of Multiple Cancers Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Early Detection of Multiple Cancers Sales Value, 2019-2030
6.8.2 Southeast Asia Early Detection of Multiple Cancers Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Early Detection of Multiple Cancers Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Early Detection of Multiple Cancers Sales Value, 2019-2030
6.9.2 India Early Detection of Multiple Cancers Sales Value by Type (%), 2023 VS 2030
6.9.3 India Early Detection of Multiple Cancers Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Grail
7.1.1 Grail Profile
7.1.2 Grail Main Business
7.1.3 Grail Early Detection of Multiple Cancers Products, Services and Solutions
7.1.4 Grail Early Detection of Multiple Cancers Revenue (US$ Million) & (2019-2024)
7.1.5 Grail Recent Developments
7.2 Exact Sciences
7.2.1 Exact Sciences Profile
7.2.2 Exact Sciences Main Business
7.2.3 Exact Sciences Early Detection of Multiple Cancers Products, Services and Solutions
7.2.4 Exact Sciences Early Detection of Multiple Cancers Revenue (US$ Million) & (2019-2024)
7.2.5 Exact Sciences Recent Developments
7.3 Foundation Medicine
7.3.1 Foundation Medicine Profile
7.3.2 Foundation Medicine Main Business
7.3.3 Foundation Medicine Early Detection of Multiple Cancers Products, Services and Solutions
7.3.4 Foundation Medicine Early Detection of Multiple Cancers Revenue (US$ Million) & (2019-2024)
7.3.5 AnchorDx Recent Developments
7.4 AnchorDx
7.4.1 AnchorDx Profile
7.4.2 AnchorDx Main Business
7.4.3 AnchorDx Early Detection of Multiple Cancers Products, Services and Solutions
7.4.4 AnchorDx Early Detection of Multiple Cancers Revenue (US$ Million) & (2019-2024)
7.4.5 AnchorDx Recent Developments
7.5 Guardant Health
7.5.1 Guardant Health Profile
7.5.2 Guardant Health Main Business
7.5.3 Guardant Health Early Detection of Multiple Cancers Products, Services and Solutions
7.5.4 Guardant Health Early Detection of Multiple Cancers Revenue (US$ Million) & (2019-2024)
7.5.5 Guardant Health Recent Developments
7.6 Burning Rock Biotech
7.6.1 Burning Rock Biotech Profile
7.6.2 Burning Rock Biotech Main Business
7.6.3 Burning Rock Biotech Early Detection of Multiple Cancers Products, Services and Solutions
7.6.4 Burning Rock Biotech Early Detection of Multiple Cancers Revenue (US$ Million) & (2019-2024)
7.6.5 Burning Rock Biotech Recent Developments
7.7 GENECAST
7.7.1 GENECAST Profile
7.7.2 GENECAST Main Business
7.7.3 GENECAST Early Detection of Multiple Cancers Products, Services and Solutions
7.7.4 GENECAST Early Detection of Multiple Cancers Revenue (US$ Million) & (2019-2024)
7.7.5 GENECAST Recent Developments
7.8 Labporatory for Advanced Medicine and Health Group
7.8.1 Labporatory for Advanced Medicine and Health Group Profile
7.8.2 Labporatory for Advanced Medicine and Health Group Main Business
7.8.3 Labporatory for Advanced Medicine and Health Group Early Detection of Multiple Cancers Products, Services and Solutions
7.8.4 Labporatory for Advanced Medicine and Health Group Early Detection of Multiple Cancers Revenue (US$ Million) & (2019-2024)
7.8.5 Labporatory for Advanced Medicine and Health Group Recent Developments
7.9 Singlera Genomics
7.9.1 Singlera Genomics Profile
7.9.2 Singlera Genomics Main Business
7.9.3 Singlera Genomics Early Detection of Multiple Cancers Products, Services and Solutions
7.9.4 Singlera Genomics Early Detection of Multiple Cancers Revenue (US$ Million) & (2019-2024)
7.9.5 Singlera Genomics Recent Developments
7.10 Johns Hopkins Medicine
7.10.1 Johns Hopkins Medicine Profile
7.10.2 Johns Hopkins Medicine Main Business
7.10.3 Johns Hopkins Medicine Early Detection of Multiple Cancers Products, Services and Solutions
7.10.4 Johns Hopkins Medicine Early Detection of Multiple Cancers Revenue (US$ Million) & (2019-2024)
7.10.5 Johns Hopkins Medicine Recent Developments
7.11 Bioscience
7.11.1 Bioscience Profile
7.11.2 Bioscience Main Business
7.11.3 Bioscience Early Detection of Multiple Cancers Products, Services and Solutions
7.11.4 Bioscience Early Detection of Multiple Cancers Revenue (US$ Million) & (2019-2024)
7.11.5 Bioscience Recent Developments
7.12 Genetron Holdings
7.12.1 Genetron Holdings Profile
7.12.2 Genetron Holdings Main Business
7.12.3 Genetron Holdings Early Detection of Multiple Cancers Products, Services and Solutions
7.12.4 Genetron Holdings Early Detection of Multiple Cancers Revenue (US$ Million) & (2019-2024)
7.12.5 Genetron Holdings Recent Developments
7.13 Shenzhen Ruisi
7.13.1 Shenzhen Ruisi Profile
7.13.2 Shenzhen Ruisi Main Business
7.13.3 Shenzhen Ruisi Early Detection of Multiple Cancers Products, Services and Solutions
7.13.4 Shenzhen Ruisi Early Detection of Multiple Cancers Revenue (US$ Million) & (2019-2024)
7.13.5 Shenzhen Ruisi Recent Developments
7.14 Shanghai Majorbio Bio-Pharm Technology
7.14.1 Shanghai Majorbio Bio-Pharm Technology Profile
7.14.2 Shanghai Majorbio Bio-Pharm Technology Main Business
7.14.3 Shanghai Majorbio Bio-Pharm Technology Early Detection of Multiple Cancers Products, Services and Solutions
7.14.4 Shanghai Majorbio Bio-Pharm Technology Early Detection of Multiple Cancers Revenue (US$ Million) & (2019-2024)
7.14.5 Shanghai Majorbio Bio-Pharm Technology Recent Developments
7.15 Shanghai Gurong
7.15.1 Shanghai Gurong Profile
7.15.2 Shanghai Gurong Main Business
7.15.3 Shanghai Gurong Early Detection of Multiple Cancers Products, Services and Solutions
7.15.4 Shanghai Gurong Early Detection of Multiple Cancers Revenue (US$ Million) & (2019-2024)
7.15.5 Shanghai Gurong Recent Developments
8 Industry Chain Analysis
8.1 Early Detection of Multiple Cancers Industrial Chain
8.2 Early Detection of Multiple Cancers Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Early Detection of Multiple Cancers Sales Model
8.5.2 Sales Channel
8.5.3 Early Detection of Multiple Cancers Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Grail
Exact Sciences
Foundation Medicine
AnchorDx
Guardant Health
Burning Rock Biotech
GENECAST
Labporatory for Advanced Medicine and Health Group
Singlera Genomics
Johns Hopkins Medicine
Bioscience
Genetron Holdings
Shenzhen Ruisi
Shanghai Majorbio Bio-Pharm Technology
Shanghai Gurong

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂